204.21 +0.39 (0.19%)
Pre-market: 5:12AM EST
|Bid||199.63 x 1000|
|Ask||206.32 x 1000|
|Day's range||201.75 - 205.55|
|52-week range||117.06 - 218.00|
|Beta (5Y monthly)||0.28|
|PE ratio (TTM)||30.02|
|Earnings date||27 Apr 2021|
|Forward dividend & yield||3.40 (1.67%)|
|Ex-dividend date||11 Feb 2021|
|1y target est||216.14|
Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in development. Under the terms of the agreement, Lilly and Welldoc will collaborate to create a new version of the BlueStar® insulin management solution that integrates insulin dosing data for several Lilly insulins. Lilly will commercialize the pen platform, which will include the new app and Lilly's connected insulin pen solutions.
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 9:10 a.m., Eastern Time.
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (NYSE: LLY). A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.